Cargando…

Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 M(pro) inhibitor in animal models

Nirmatrelvir (PF-07321332; NMV) the antiviral component of PAXLOVID™ is a potent and selective inhibitor of the SARS-CoV-2 main protease (M(pro)), which plays a critical role in viral replication. PAXLOVID, comprised of nirmatrelvir and ritonavir (used as a pharmacokinetic enhancer), is an oral ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Catlin, N.R., Bowman, C.J., Campion, S.N., Cheung, J.R., Nowland, W.S., Sathish, J.G., Stethem, C.M., Updyke, L., Cappon, G.D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801796/ https://www.ncbi.nlm.nih.gov/pubmed/35101563 http://dx.doi.org/10.1016/j.reprotox.2022.01.006

Ejemplares similares

Total synthesis of antiviral drug, nirmatrelvir (PF-07321332)
por: Shekhar, Chandra, et al.
Publicado: (2022)

PF‐07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID‐19 patients
por: Hau, Raymond K., et al.
Publicado: (2022)

The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations
por: Joyce, Ryan P., et al.
Publicado: (2022)

Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management
por: Heskin, Joseph, et al.
Publicado: (2022)

Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332
por: Li, Jian, et al.
Publicado: (2022)

Structural basis of main proteases of HCoV-229E bound to inhibitor PF-07304814 and PF-07321332
por: Zhou, Yanru, et al.
Publicado: (2023)

Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332
por: Zhao, Yao, et al.
Publicado: (2021)

Insights into the binding and covalent inhibition mechanism of PF-07321332 to SARS-CoV-2 M(pro)
por: Ngo, Son Tung, et al.
Publicado: (2022)

Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease
por: Macchiagodena, Marina, et al.
Publicado: (2022)

The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
por: Abdelnabi, Rana, et al.
Publicado: (2022)

Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332
por: Pavan, Matteo, et al.
Publicado: (2021)

Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations
por: Ahmad, Bilal, et al.
Publicado: (2021)

EE495 Threshold Price in the US to Achieve Cost-Effective Use of Molnupiravir and PF-07321332/Ritonavir for the Prevention of Severe COVID-19 in High-Risk Adults
por: Majda, T, et al.
Publicado: (2022)

Interaction of the new inhibitor paxlovid (PF-07321332) and ivermectin with the monomer of the main protease SARS-CoV-2: A volumetric study based on molecular dynamics, elastic networks, classical thermodynamics and SPT
por: Alvarado, Ysaias José, et al.
Publicado: (2022)

Lack of effects on female fertility and prenatal and postnatal offspring development in rats with BNT162b2, a mRNA-based COVID-19 vaccine
por: Bowman, Christopher J., et al.
Publicado: (2021)

The Remarkable Selectivity of Nirmatrelvir
por: Duveau, Damien Y., et al.
Publicado: (2022)

Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022)

Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

Correction to: Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022)

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19
por: Robinson, Philip, et al.
Publicado: (2023)

Effect of Oral Nirmatrelvir on Long COVID Symptoms: 4 Cases and Rationale for Systematic Studies
por: Peluso, Michael J., et al.
Publicado: (2022)

Benefits of nirmatrelvir–ritonavir remain unproven for some populations
por: McDonald, Emily G., et al.
Publicado: (2022)

Association nirmatrelvir/ritonavir contre la COVID-19
por: McDonald, Emily G., et al.
Publicado: (2022)

Nirmatrelvir wirkt auch gegen Omikron
por: Gesierich, Wolfgang
Publicado: (2023)

Focal epilepsy presenting as a bath-induced paroxysmal event/breath-holding attack
por: Stutchfield, C.J., et al.
Publicado: (2014)

Development of the Commercial Manufacturing Process for Nirmatrelvir in 17 Months
por: Allais, Christophe, et al.
Publicado: (2023)

Early Racial and Ethnic Disparities in the Prescription of Nirmatrelvir for COVID-19
por: Tarabichi, Yasir, et al.
Publicado: (2023)

523. Efficacy and Safety of Nirmatrelvir/Ritonavir for COVID-19 in Adolescents
por: Lee, Kiriam Escobar, et al.
Publicado: (2023)

Possible medication error risks with nirmatrelvir+ritonavir
Publicado: (2022)

Nirmatrelvir wirkt auch in der Omikron-Welle
por: Gesierich, Wolfgang
Publicado: (2022)

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
por: Lu, Jiayue, et al.
Publicado: (2023)

Nirmatrelvir and Molnupiravir and Post–COVID-19 Condition in Older Patients
por: Fung, Kin Wah, et al.
Publicado: (2023)

Obstetric Staff Deployment to Help With Staffing Surges From COVID-19
por: Updyke, Stacey
Publicado: (2021)

Identification of Immunodominant Responses to the Plasmodium falciparum Antigens PfUIS3, PfLSA1 and PfLSAP2 in Multiple Strains of Mice
por: Longley, Rhea J., et al.
Publicado: (2015)

Reply to “Misclassification of PfEH1 and PfEH2 as Epoxide Hydrolases”
por: Goldberg, Daniel E., et al.
Publicado: (2017)

COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy
por: Coulson, J.M., et al.
Publicado: (2022)

Drug Interactions With a Short Course of Nirmatrelvir and Ritonavir: Prescribers and Patients Beware
por: Ratain, Mark J., et al.
Publicado: (2022)

Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
por: Anderson, Annaliesa S., et al.
Publicado: (2022)

Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19
por: Reis, Stefanie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vrrja1h3jjm3r813u19hb0vsef